Skip to main content
Premium Trial:

Request an Annual Quote

454 Extends License to Biotage Sequencing Technology

NEW YORK, Sept. 17 (GenomeWeb News) - 454 has extended a one-year license to now include exclusive rights to synthesizing technologies owned by Biotage, the company said today.

New Haven, Conn.-based 454 has obtains the rights to sequencing by synthesis and pyrophosphate-based sequencing for whole genome and other high density and high-throughput applications.

 

The company's minimum royalty payment of $1 million annually will increase to $1.25 million a year for two years, and 454 has the right to continue the agreement throughout the lifetime of the patents. 454 has already paid $3 million toward an estimated minimum of $13 million through 2014, Stockholm, Sweden-based Biotage said.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.